Forbion Capitals: Two new oncology experts
10.12.2012 - Forbion Capital Partners (Naarden, Holland) has hired two oncology experts as scientific advisors to its funds. Dr. Kapil Dhingra (Photo) is a former Global Leader Oncology at Roche, while John Kastelein is a Professor of Medicine at the University of Amsterdam’s Department of Vascular Medicine.
The two will be advising on oncology and metabolic disease investment opportunities respectively. Dhingra is a medical oncologist and physician/scientist. The founder of KAPital Consulting LLC used to head Roche's Disease Biology Leadership Team. Dinghra became VP Oncology at the Swiss pharma giant after joining the company in 1999. There he played a key role in the expansion of the firm's oncology department. Before that he had worked as a Clinical Research Physician at Eli Lilly and at the M.D.. Anderson Cancer Center in Houston (US). A former board member at BioVex and Micromet, Dhingra is also on the board of Exosome Diagnostics. Kastelein is a co-founder of Amsterdam Molecular Therapeutics N.V. (now uniQure B.V.) and Xenon Pharmaceuticals Inc. (formerly Xenon Genetics Inc.).